DocGo Inc. agreed November 13, 2026: Lee Bienstock will depart March 31, 2027, unless extended or earlier terminated. He remains CEO until a successor starts, then serves as senior advisor; transition pay is $90,000 monthly and conditional severance is $785,000.
DCGO · DocGo Inc.
The latest filing states the doubt was alleviated.
“While these plans carry meaningful inherent risk to operations, the Company’s management and the Board of Directors have evaluated these conditions in totality and conclude it is probable that, when implemented, the plans will be sufficient to alleviate substantial doubt about the Company’s ability to continue as a going concern for the next twelve months.”View the 10-Q filed Nov 9, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
DCGO announced CEO Lee Bienstock will transition out and remain through at least March 31, 2027. Full-year 2026 revenue guidance fell to approximately $300 million, while adjusted EBITDA loss guidance stayed at $17 million to $22 million.
For the three months ended September 30, 2026, DocGo reported revenues of $73.4 million, up 3.7%, and a net loss of $18.3 million versus $29.7 million for the three months ended September 30, 2025.
DocGo reported revenue of $73.4 million, up from $70.8 million, and net income of ($18.1) million. Full-year 2026 revenue guidance fell to approximately $300 million from $305-$310 million; adjusted EBITDA guidance remained ($17-$22) million, and a CEO search began.
DocGo entered an amended Hicuity and Ambulnz credit agreement providing $52,000,000 Term Loan A, $12,500,000 Term Loan B and C, and $25,000,000 Term Loan D at Term SOFR plus 7.50%, due December 6, 2029. It also issued a 4,000,000-share warrant.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 9, 2026TL;DR. DocGo returned to year-over-year revenue growth, improved gross margin and adjusted SG&A, and expects positive EBITDA in 2027. However, revenue guidance was reduced, cash fell to $19.1 million, mobile-health margin and care-in-the-home volume declined, fuel costs remained a headwind, and a CEO transition introduces execution risk.
- + Q3 revenue was $73.4 million versus $70.8 million a year earlier, marking the company's first year-over-year revenue increase since Q2 2023.
- + Adjusted EBITDA loss narrowed to $3.2 million from $7.2 million in Q3 2025.
- + Gross margin improved to 33.3% from 30.5% in Q2.
- + Medical transportation revenue rose to $53.3 million from $50.1 million in Q3 2025 and reached a quarterly record.
- + Adjusted SG&A declined to $28.7 million from $29.7 million in Q2 and $30.8 million in Q1.
- + Management anticipates positive EBITDA for full-year 2027.
- − Full-year 2026 revenue guidance was reduced to approximately $300 million from $305 million to $310 million.
- − Unrestricted cash declined to $19.1 million at September 30 from $25.2 million at June 30.
- − Mobile health adjusted gross margin fell to 29.7% from 36.2% in Q3 2025.
- − Care-in-the-home visit volume declined 26% year over year after outreach and clinical operations were deliberately reduced.
- − Higher fuel costs restrained transportation gross margin by about 52 basis points and consolidated gross margin by about 38 basis points versus the prior year.
- − The board has initiated a CEO search as Lee Bienstock's employment contract approaches expiration, creating leadership-transition and execution risk.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | -19.8M | nine months ended September 30, 2026 | — |
|
|
|||
| Adjusted EBITDA margin non-GAAP | -8.9% | nine months ended September 30, 2026 | — |
|
|
|||
| Adjusted gross margin non-GAAP | 31.8% | nine months ended September 30, 2026 | — |
| Adjusted gross profit non-GAAP | $70,751,737 | nine months ended September 30, 2026 | — |
| medical transportation gross margins | 34.7% | the third quarter | — |
| Medical Transportation Services revenue | $53.3M | the third quarter of 2026 | +6.3% |
|
|
|||
| Mobile Health Services revenue | $20.2M | the third quarter of 2026 | -2.4% |
|
|
|||
| patients assigned by the Company's payer and provider partners to engage for care gap closure se | 1.8M | Q3 2026 | — |
|
|
|||
| Average trip price | $426 | the three months ended June 30, 2026 filing | — |
| Hicuity trailing 12-month adjusted EBITDA non-GAAP | 4.5M | trailing 12-month basis | — |
| Hicuity trailing 12-month revenue | 65M | trailing 12-month basis | — |
| U.S. trip volumes | 80,447 | the three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DCGO
this stock
DocGo Inc.
|
$17.37M | -80.0% | -47.7% | — | 2.2% |
|
HCA
HCA Healthcare, Inc.
|
$99.51B | +2.0% | +7.1% | 15.8 | 2.3% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$33.07B | +2.4% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$21.60B | +36.5% | +0.9% | 7.9 | 2.2% |
|
EHC
Encompass Health Corp
|
$13.24B | +27.1% | +10.5% | 21.1 | 3.7% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 13, 2026
- This year
- 22
DocGo Inc. agreed November 13, 2026: Lee Bienstock will depart March 31, 2027, unless extended or earlier terminated. He remains CEO until a successor starts, then serves as senior advisor; transition pay is $90,000 monthly and conditional severance is $785,000.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DCGO | -24.3% | -33.9% | -73.3% | -28.9% | -80.0% |
| SPY | -3.9% | -5.6% | -3.5% | -3.4% | +7.1% |
| vs SPY | -20.4% | -28.4% | -69.9% | -25.5% | -87.1% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.